Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7141 to 7155 of 8314 results

  1. Omburtamab for treating relapsed neuroblastoma [ID1664]

    In development Reference number: GID-TA10608 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]

    Discontinued Reference number: GID-TA10609

    Technology appraisal guidance
    Discontinued

  3. Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751]

    Discontinued Reference number: GID-TA10616

    Technology appraisal guidance
    Discontinued

  4. Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]

    Discontinued Reference number: GID-TA10617

    Technology appraisal guidance
    Discontinued

  5. Crizotinib for treating metastatic c-MET exon 14-positive non-small-cell lung cancer [ID1472]

    Discontinued Reference number: GID-TA10625

    Technology appraisal guidance
    Discontinued

  6. Intravenous zanamivir for treating influenza in hospital [ID1196]

    Discontinued Reference number: GID-TA10298

    Technology appraisal guidance
    Discontinued

  7. Lenalidomide for untreated follicular lymphoma ID1245

    Discontinued Reference number: GID-TA10308

    Technology appraisal guidance
    Discontinued

  8. Idebenone for treating Duchenne muscular dystrophy [ID1092]

    Discontinued Reference number: GID-TA10310

    Technology appraisal guidance
    Discontinued

  9. Durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1331]

    Discontinued Reference number: GID-TA10318

    Technology appraisal guidance
    Discontinued

  10. Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]

    Discontinued Reference number: GID-TA10321

    Technology appraisal guidance
    Discontinued

  11. Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]

    Discontinued Reference number: GID-TA10324

    Technology appraisal guidance
    Discontinued

  12. Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer [ID1413]

    Discontinued Reference number: GID-TA10329

    Technology appraisal guidance
    Discontinued

  13. Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

    Discontinued Reference number: GID-TA10332

    Technology appraisal guidance
    Discontinued

  14. Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

    Discontinued Reference number: GID-TA10337

    Technology appraisal guidance
    Discontinued

  15. Atezolizumab for untreated advanced renal cell carcinoma [ID1365]

    Discontinued Reference number: GID-TA10338

    Technology appraisal guidance
    Discontinued